Solvent interaction analysis as a proteomic approach to structure-based biomarker discovery and clinical diagnostics

被引:9
|
作者
Zaslavsky, Boris Y. [1 ]
Uversky, Vladimir N. [2 ,3 ]
Chait, Arnon [1 ]
机构
[1] Cleveland Diagnost, Cleveland, OH 44114 USA
[2] Univ S Florida, Dept Mol Med, Morsani Coll Med, Tampa, FL 33612 USA
[3] Univ S Florida, Byrd Alzheimers Res Inst, Morsani Coll Med, Tampa, FL 33612 USA
关键词
structural biomarkers; protein biomarkers; solvent interaction analysis; aqueous two-phase partitioning; glycosylation; cancer biomarkers; aqueous two-phase systems; proteomics; AQUEOUS 2-PHASE SYSTEMS; MASS-SPECTROMETRIC IMMUNOASSAY; PROSTATE-SPECIFIC ANTIGEN; BREAST-CANCER; WATER INTERACTIONS; CORE-FUCOSYLATION; PANCREATIC-CANCER; N-GLYCOSYLATION; PROTEINS; SERUM;
D O I
10.1586/14789450.2016.1116945
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Proteins have several measurable features in biological fluids that may change under pathological conditions. The current disease biomarker discovery is mostly based on protein concentration in the sample as the measurable feature. Changes in protein structures, such as post-translational modifications and in protein-partner interactions are known to accompany pathological processes. Changes in glycosylation profiles are well-established for many plasma proteins in various types of cancer and other diseases. The solvent interaction analysis method is based on protein partitioning in aqueous two-phase systems and is highly sensitive to changes in protein structure and protein-protein- and protein-partner interactions while independent of the protein concentration in the biological sample. It provides quantitative index: partition coefficient representing changes in protein structure and interactions with partners. The fundamentals of the method are presented with multiple examples of applications of the method to discover and monitor structural protein biomarkers as disease-specific diagnostic indicators.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 50 条
  • [1] ProteinChips: the essential tools for proteomic biomarker discovery and future clinical diagnostics
    Clarke, W
    Chan, DW
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2005, 43 (12) : 1279 - 1280
  • [2] Proteomic-based biomarker discovery for development of next generation diagnostics
    Akbar Khalilpour
    Tugba Kilic
    Saba Khalilpour
    Mario Moisés Álvarez
    Iman K. Yazdi
    Applied Microbiology and Biotechnology, 2017, 101 : 475 - 491
  • [3] Proteomic-based biomarker discovery for development of next generation diagnostics
    Khalilpour, Akbar
    Kilic, Tugba
    Khalilpour, Saba
    Alvarez, Mario Moises
    Yazdi, Iman K.
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2017, 101 (02) : 475 - 491
  • [4] The biomarker pipeline: Novel microfluidic instrumentation for advancing proteomic discovery to clinical diagnostics
    Herr, Amy E.
    2007 IEEE/NIH LIFE SCIENCE SYSTEMS AND APPLICATIONS WORKSHOP, 2007, : 5 - 8
  • [5] Biomarker discovery in MS: A proteomic approach
    Krupp, Lauren
    Rithidech, Kanokporn
    NEUROLOGY, 2008, 70 (11) : A135 - A135
  • [6] Incorporating clinical information in proteomic data analysis for biomarker discovery
    Zhang, Z.
    White, C.
    Chan, D.
    MOLECULAR & CELLULAR PROTEOMICS, 2005, 4 (08) : S169 - S169
  • [7] Proteomic Approaches in Biomarker Discovery: New Perspectives in Cancer Diagnostics
    Hudler, Petra
    Kocevar, Nina
    Komel, Radovan
    SCIENTIFIC WORLD JOURNAL, 2014,
  • [8] Highly Multiplexed Proteomic Platform for Biomarker Discovery, Diagnostics, and Therapeutics
    Mehan, Michael R.
    Ostroff, Rachel
    Wilcox, Sheri K.
    Steele, Fintan
    Schneider, Daniel
    Jarvis, Thale C.
    Baird, Geoffrey S.
    Gold, Larry
    Janjic, Nebojsa
    COMPLEMENT THERAPEUTICS, 2013, 735 : 283 - 300
  • [9] Biomarker discovery in neurodegenerative diseases: A proteomic approach
    Shi, Min
    Caudle, W. Michael
    Zhang, Jing
    NEUROBIOLOGY OF DISEASE, 2009, 35 (02) : 157 - 164
  • [10] Targeted proteomic strategy for clinical biomarker discovery
    Schiess, Ralph
    Wollscheid, Bernd
    Aebersold, Ruedi
    MOLECULAR ONCOLOGY, 2009, 3 (01) : 33 - 44